← Insmed overview

Insmed vs Regeneron Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Insmed Inc (INSM)

Q3 2026
▲4

Insmed's Brinsupri Launch Accelerates, Peak-Sales Target Raised to $14B

  • Q2 loss narrows sharply, Brinsupri guidance raised Insmed's Q2 net loss shrank to $13.2 million from $321.7 million a year earlier, and product revenue nearly quadrupled to $425.5 million. Brinsupri sales hit $309.2 million, up 49% from the prior quarter, and management raised 2026 Brinsupri guidance to $1.25–$1.40 billion. The stock jumped 33% on the news.

    This is the period's biggest price-moving event and shows the core business is performing far better than expected.

  • Peak-sales estimate raised to over $14 billion Management now sees peak sales for its three lead programs exceeding $14 billion, a 75% increase. More than $7 billion is tied to already-launched Brinsupri, but over $6 billion depends on TPIP, which is still in Phase III trials for only two of four target indications. Insmed ended June with $1.2 billion in cash, enough to reach profitability in 2027 without raising capital.

    This gives investors a long-term growth target and shows the company can fund itself, but also flags the pipeline risk.

  • Positive 12-month TPIP data supports Phase 3 launch Insmed reported positive 12-month data for TPIP in pulmonary arterial hypertension, with sustained improvements in exercise capacity and no new safety signals. This supports launching the PALM-PAH Phase 3 trial. TPIP is a key part of the $6 billion-plus peak-sales opportunity that still needs late-stage success.

    It de-risks a major pipeline asset that underpins a large chunk of the raised peak-sales estimate.

  • EMBARC to run 3,000-patient brensocatib study The European bronchiectasis research group EMBARC will collaborate with Insmed on a 3,000-patient study of brensocatib (Brinsupri) across six countries. The study aims to show whether early treatment can change the disease course, which could expand use and strengthen the case for the drug beyond current approvals.

    It signals strong clinical interest and potential for broader use, supporting long-term demand for the main growth driver.

July 2026
▲4

Insmed's Brinsupri Launch Accelerates, Peak-Sales Target Raised to $14B

  • Q2 loss narrows sharply, Brinsupri guidance raised Insmed's Q2 net loss shrank to $13.2 million from $321.7 million a year earlier, and product revenue nearly quadrupled to $425.5 million. Brinsupri sales hit $309.2 million, up 49% from the prior quarter, and management raised 2026 Brinsupri guidance to $1.25–$1.40 billion. The stock jumped 33% on the news.

    This is the period's biggest price-moving event and shows the core business is performing far better than expected.

  • Peak-sales estimate raised to over $14 billion Management now sees peak sales for its three lead programs exceeding $14 billion, a 75% increase. More than $7 billion is tied to already-launched Brinsupri, but over $6 billion depends on TPIP, which is still in Phase III trials for only two of four target indications. Insmed ended June with $1.2 billion in cash, enough to reach profitability in 2027 without raising capital.

    This gives investors a long-term growth target and shows the company can fund itself, but also flags the pipeline risk.

  • Positive 12-month TPIP data supports Phase 3 launch Insmed reported positive 12-month data for TPIP in pulmonary arterial hypertension, with sustained improvements in exercise capacity and no new safety signals. This supports launching the PALM-PAH Phase 3 trial. TPIP is a key part of the $6 billion-plus peak-sales opportunity that still needs late-stage success.

    It de-risks a major pipeline asset that underpins a large chunk of the raised peak-sales estimate.

  • EMBARC to run 3,000-patient brensocatib study The European bronchiectasis research group EMBARC will collaborate with Insmed on a 3,000-patient study of brensocatib (Brinsupri) across six countries. The study aims to show whether early treatment can change the disease course, which could expand use and strengthen the case for the drug beyond current approvals.

    It signals strong clinical interest and potential for broader use, supporting long-term demand for the main growth driver.

Latest
▲4

Insmed's Brinsupri Launch Accelerates, Peak-Sales Target Raised to $14B

  • Q2 loss narrows sharply, Brinsupri guidance raised Insmed's Q2 net loss shrank to $13.2 million from $321.7 million a year earlier, and product revenue nearly quadrupled to $425.5 million. Brinsupri sales hit $309.2 million, up 49% from the prior quarter, and management raised 2026 Brinsupri guidance to $1.25–$1.40 billion. The stock jumped 33% on the news.

    This is the period's biggest price-moving event and shows the core business is performing far better than expected.

  • Peak-sales estimate raised to over $14 billion Management now sees peak sales for its three lead programs exceeding $14 billion, a 75% increase. More than $7 billion is tied to already-launched Brinsupri, but over $6 billion depends on TPIP, which is still in Phase III trials for only two of four target indications. Insmed ended June with $1.2 billion in cash, enough to reach profitability in 2027 without raising capital.

    This gives investors a long-term growth target and shows the company can fund itself, but also flags the pipeline risk.

  • Positive 12-month TPIP data supports Phase 3 launch Insmed reported positive 12-month data for TPIP in pulmonary arterial hypertension, with sustained improvements in exercise capacity and no new safety signals. This supports launching the PALM-PAH Phase 3 trial. TPIP is a key part of the $6 billion-plus peak-sales opportunity that still needs late-stage success.

    It de-risks a major pipeline asset that underpins a large chunk of the raised peak-sales estimate.

  • EMBARC to run 3,000-patient brensocatib study The European bronchiectasis research group EMBARC will collaborate with Insmed on a 3,000-patient study of brensocatib (Brinsupri) across six countries. The study aims to show whether early treatment can change the disease course, which could expand use and strengthen the case for the drug beyond current approvals.

    It signals strong clinical interest and potential for broader use, supporting long-term demand for the main growth driver.

Regeneron Pharmaceuticals Inc (REGN)

Q3 2026
▲2▼2

Regeneron's Q3: pipeline wins, Sanofi deal, but melanoma setback

  • Strong Q2 results and pipeline progress Regeneron reported Q2 revenue up 17% to $4.29 billion, received FDA priority review for cemdisiran in myasthenia gravis, and won approval for Pasatru in FOP disease. These advances support future growth.

    These positive developments drove investor optimism and supported the stock.

  • Expanded Sanofi deal and obesity drug data Regeneron expanded its Sanofi partnership with $1 billion upfront and four pipeline therapies. Its obesity drug trevogrumab preserved about 70% of muscle loss in a Phase 2 trial, showing promise in a large market.

    The deal and trial data are new positive catalysts for Regeneron's growth outlook.

  • Failed melanoma trial and lawsuits A failed melanoma trial led to class-action lawsuits and an $11 billion market-value loss. This setback raised concerns about pipeline execution and weighed on the stock.

    This was a major negative event that hurt investor confidence and the share price.

  • Eylea competition and Sanofi deal disappointment Eylea faces biosimilar and competitive threats, notably Kodiak's less-frequent-dosing eye drug. The Sanofi deal left Dupixent profit-sharing unchanged, disappointing some investors and briefly pressuring shares.

    These competitive and deal-related concerns created headwinds for the stock.

August 2026
▲2▼1

Regeneron's strong Q2 and pipeline wins offset by legal and competitive risks

  • Strong Q2 earnings and margin improvement Regeneron beat Q2 estimates with revenue up 17% to $4.29 billion, driven by Dupixent and high-dose Eylea. Repaying the Sanofi Development Balance should improve margins, and buybacks and dividends support shareholder value.

    This point explains the positive financial performance that drove the stock during the period.

  • Pipeline progress and new Sanofi deal FDA approval of Pasatru for rare FOP disease validates Regeneron's drug platform. A new Sanofi deal adds $1 billion upfront and four pipeline therapies, strengthening the pipeline and providing external validation.

    This point highlights key pipeline and partnership developments that boosted investor sentiment.

  • Pipeline uncertainty and Eylea competition Mixed melanoma trial results and increasing competition for Eylea add pipeline uncertainty. These factors offset strong commercial performance and contribute to a balanced but cautious outlook.

    This point explains the competitive and pipeline challenges that acted as a counterweight to positive developments.

Latest
▲2▼2

Regeneron's Sanofi deal and pipeline progress offset by Eylea competition and lawsuits

  • Sanofi deal expands pipeline with $1B upfront Regeneron and Sanofi agreed to jointly develop four long-acting immunology therapies, led by REGN20423, in a deal worth up to $8 billion including $1 billion upfront. This brings cash and pipeline growth, supporting future revenue and the stock.

    This is a major new partnership that directly boosts Regeneron's pipeline and cash, a key positive driver.

  • Securities class action lawsuits weigh on sentiment Multiple law firms filed class actions alleging Regeneron made false statements about its Fianlimab-Libtayo trial, causing investor losses. The legal uncertainty and potential reputational damage pressure the stock, though the company denies wrongdoing.

    These lawsuits are a new negative overhang that could affect investor confidence and lead to financial penalties.

  • Mixed melanoma trial results lead to pullback Regeneron's melanoma drug trial produced mixed results, causing shares to give back some gains. This setback raises doubts about the drug's potential and adds to pipeline uncertainty, weighing on the stock.

    This is a new clinical setback that directly impacts Regeneron's oncology pipeline and investor expectations.

  • Buybacks and dividend support shareholder value Regeneron confirmed its quarterly dividend, updated on share repurchases, and reported Q2 results. With the stock trading below fair value estimates, these capital returns and pipeline progress support the shares.

    This shows management's commitment to returning cash and the stock's valuation appeal, a positive for investors.

September 2026
▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

  • Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.

    This is the period's biggest positive fundamental driver of REGN's value.

  • Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.

    It is a concrete capital event that improves future profitability.

  • FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.

    A new FDA approval is a fresh product and pipeline milestone for REGN.

  • Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.

    This is the main negative overhang on REGN this period.

July 2026
▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

Q2 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

June 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.